AB0700 GOLIMUMAB PERSISTENCE IN BIOLOGIC NAÏVE AND NON-NAÏVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF THE GO-PRACTICE STUDY
Autor: | Florence Tubach, Jean Ouaniche, Bruno Fautrel, Philippe Bertin, Eric Lespessailles, Philippe Goupille, N Gouyette, Naoual Harid, René-Marc Flipo, Jean-Marie Fayette |
---|---|
Rok vydání: | 2019 |
Předmět: |
030203 arthritis & rheumatology
0301 basic medicine medicine.medical_specialty business.industry medicine.disease Golimumab 03 medical and health sciences Psoriatic arthritis 030104 developmental biology 0302 clinical medicine Quality of life Family medicine Cohort Medicine Observational study Functional ability Medical prescription business BASDAI medicine.drug |
Zdroj: | Abstracts accepted for Publication. |
Popis: | Background: Golimumab (GLM) was the latest anti-TNFα therapy to be indicated in the treatment of chronic inflammatory rheumatic diseases. The pivotal GO-AFTER study [1] and the ongoing observational GO-BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received biologics. However, clinical studies of GLM in axial spondyloarthritis (AS) are lacking. Using data from the GO-PRACTICE study, we examined GLM persistence in patients with aS. Objectives: Primary objective was to estimate GLM persistence at 2 years from initial prescription, as a first line of treatment (in biologic naive patients:BN) and as a second or further line of treatment (in biologic pretreated patients:BP). Persistence was estimated with the Kaplan-Meier method. Secondary outcomes included assessing disease activity (ASDAS) evolution and patient-reported evaluations of disease activity (BASDAI), pain (VAS), functional ability (HAQ) and quality of life (EQ-5D and SF-12). Methods: Observational, prospective, multicenter French study, that recruited adult patients with RA, psoriatic arthritis or aS, who were newly prescribed GLM. Patients were followed-up over 2 years; data were collected at baseline (BL), 1 year and 2 years. This abstract presents results from the aS cohort of GO-PRACTICE. Results: 478 patients with aS (constituting 63% of the total cohort) from 134 sites were included from January 2015 to March 2016. Mean age was 43 years, 55% were female; 61% were BN (n=291) and 39% (n=187) were BP. Mean duration of aS was 5.5 and 10.7 years in BN and BP patients, respectively (P Conclusion: GLM is associated with clinical improvements and good persistence in aS patients, especially those who are biologic naive. References [1] Smolen JS, et al; arthritis research & therapy2015,17:14 Disclosure of interests: Philippe Bertin Grant/research support from: Financial compensation received from MSD on a pro-rota basis for participation in Scientific Committee meetings and functions for this study, Philippe Goupille Grant/research support from: Financial compensation received from MSD on a pro-rota basis for participation in Scientific Committee meetings and functions for this study, Speakers bureau: abbvie, Biogaran, BMS, Hospira, Janssen, MSD, Pfizer, Sanofi-Genzyme, UCB, Florence Tubach Grant/research support from: Financial compensation received from MSD on a pro-rota basis for participation in Scientific Committee meetings and functions for this study, Jean OUANICHE Grant/research support from: Financial compensation received from MSD on a pro-rota basis for active participation in Scientific Committee meetings and functions, Eric Lespessailles Grant/research support from: Grants/research support from amgen, Eli Lily, MSD, UCB., Consultant for: Consultant for amgen, Expanscience, Eli Lilly, MSD, UCB., Najat Gouyette Employee of: MSD, France, Naoual HARID Employee of: MSD, France, jean-marie Fayette Consultant for: Contract Research Organisation - ClinSearch, Bruno Fautrel Grant/research support from: abbVie, Lilly, MSD, Pfizer, Consultant for: abbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, NORDIC Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, Sanofi Genzyme, SOBI, UCB, Rene-Marc Flipo Consultant for: Honoraria from Novartis as steering committe of this survey |
Databáze: | OpenAIRE |
Externí odkaz: |